|Poll|June 15, 2022

POLL: Which Recent FDA Update Was Most Exciting?

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME